A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients (Q33366008)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Fortunato Ciardiello

object named as

F Ciardiello

16

0 references

author name string

F De Vita

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Orditura

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E Matano

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

R Bianco

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Carlomagno

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Infusino

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

V Damiano

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E Simeone

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M R Diadema

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E Lieto

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

P Castellano

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Pepe

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S De Placido

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Galizia

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Di Martino

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Catalano

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A R Bianco

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1644-1649

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Gastric cancer: epidemiology, pathology and treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Epidemiology of cancer: global patterns and trends

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

28 July 2018

Oxaliplatin: available data in non-colorectal gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602573

21 January 2018

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602573

21 January 2018

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602573

21 January 2018

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602573

21 January 2018

Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

31 October 2018

Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362040

31 October 2018

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rising incidence of adenocarcinoma of the esophagus and gastric cardia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602573

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6602573

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33366008&oldid=2195289610"